Eli Lilly’s ongoing collaboration with Peptron centers on a non-exclusive technical evaluation agreement signed in October 2024, allowing the pharmaceutical giant to test SmartDepot’s ultrasonic spray-dried PLGA microsphere platform for sustained-release peptide formulations. This setup explicitly limits use to internal R&D and feasibility studies, with any commercial licensing framed as a separate, optional next step that has not materialized despite multiple extensions through October 2026. Recent expansion of the research into CNS applications has not altered the pre-commercial status, while Lilly’s parallel partnerships with other sustained-release technologies have reinforced trader views that a binding technology-transfer deal remains improbable before the rapidly approaching deadline.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated13% chance
$11,314 Vol.
$11,314 Vol.
Oct 6, 2026
13% chance
$11,314 Vol.
$11,314 Vol.
Oct 6, 2026
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s ongoing collaboration with Peptron centers on a non-exclusive technical evaluation agreement signed in October 2024, allowing the pharmaceutical giant to test SmartDepot’s ultrasonic spray-dried PLGA microsphere platform for sustained-release peptide formulations. This setup explicitly limits use to internal R&D and feasibility studies, with any commercial licensing framed as a separate, optional next step that has not materialized despite multiple extensions through October 2026. Recent expansion of the research into CNS applications has not altered the pre-commercial status, while Lilly’s parallel partnerships with other sustained-release technologies have reinforced trader views that a binding technology-transfer deal remains improbable before the rapidly approaching deadline.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Market Opened: May 5, 2026, 8:02 PM ET
Volume
$11,314End Date
Oct 7, 2026Market Opened
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s ongoing collaboration with Peptron centers on a non-exclusive technical evaluation agreement signed in October 2024, allowing the pharmaceutical giant to test SmartDepot’s ultrasonic spray-dried PLGA microsphere platform for sustained-release peptide formulations. This setup explicitly limits use to internal R&D and feasibility studies, with any commercial licensing framed as a separate, optional next step that has not materialized despite multiple extensions through October 2026. Recent expansion of the research into CNS applications has not altered the pre-commercial status, while Lilly’s parallel partnerships with other sustained-release technologies have reinforced trader views that a binding technology-transfer deal remains improbable before the rapidly approaching deadline.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Volume
$11,314End Date
Oct 7, 2026Market Opened
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Eli Lilly’s ongoing collaboration with Peptron centers on a non-exclusive technical evaluation agreement signed in October 2024, allowing the pharmaceutical giant to test SmartDepot’s ultrasonic spray-dried PLGA microsphere platform for sustained-release peptide formulations. This setup explicitly limits use to internal R&D and feasibility studies, with any commercial licensing framed as a separate, optional next step that has not materialized despite multiple extensions through October 2026. Recent expansion of the research into CNS applications has not altered the pre-commercial status, while Lilly’s parallel partnerships with other sustained-release technologies have reinforced trader views that a binding technology-transfer deal remains improbable before the rapidly approaching deadline.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated
Beware of external links.
Beware of external links.
Frequently Asked Questions